MedPath

effect of milk protein concentrate in AIDS

Phase 3
Conditions
HIV,AIDS.
Human immunodeficiency virus [HIV] disease
Registration Number
IRCT20150909023957N9
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
80
Inclusion Criteria

Willingness to cooperate with the project-
CD4 level less than 500 -
Patients with AIDS whose type of disease is fully confirmed through a complete medical examination and laboratory.
Only patients with AIDS who have been on antiviral therapy for three months and are also on a consistent medication regimen should be included in this study.

Exclusion Criteria

Use of protein supplements
Drug useAlcohol, acetylcysteine, NSAIDs three months before the study
Sensitivity to dairy products
Do not take calcium supplements or any product containing it Drugs or supplements that affect the immune and inflammatory systems, such as antioxidants, sexing, omega 3, curcumin
People who, in addition to AIDS, suffer from other diseases that have oxidative stress as their etiology. Including: metabolic syndrome, diabetic foot ulcer, coronary artery disease, lung infection.
Patients with clinical conditions that pose a serious health risk, including severe kidney, liver, thyroid and parathyroid disease, gastrointestinal and heart disease and cancer

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Anthropometric evaluation. Timepoint: Beginning and end of the study. Method of measurement: Using tape measure and scales.;Evaluation of safety indicators. Timepoint: Beginning and end of the study. Method of measurement: CD4, CD8 by flow cytometry.;Evaluation of oxidative stress indices. Timepoint: Beginning and end of the study. Method of measurement: Evaluation of serum level of total antioxidant capacity (TAC) and total oxidative capacity (TOC) by Kiazist diagnostic kits.;Evaluation of inflammatory indicators. Timepoint: Beginning and end of the study. Method of measurement: The inflammatory marker ESR is determined by sodium citrate anticoagulant and CRP by ELISA and commercial German LDN kit.;Quality of Life. Timepoint: Beginning and end of the study. Method of measurement: Quality of Life Questionnaire through HIV Disability Questionnaire (HDQ).
Secondary Outcome Measures
NameTimeMethod
Evaluation of renal index. Timepoint: Beginning and end of the study. Method of measurement: Creatine test and BUN test are performed based on enzymatic method.;Evaluation of protein index. Timepoint: Beginning and end of the study. Method of measurement: Albumin levels are measured based on the Bromocresol Green test.
© Copyright 2025. All Rights Reserved by MedPath